Efficacy and safety of anlotinib maintenance therapy in limited-stage small cell lung cancer
{{output}}
Background: Effective maintenance therapy options after first-line chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) remain limited. Anlotinib, a multi-target tyrosine kinase inhibitor, was evaluated for its ef... ...
